Literature DB >> 2966745

Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide.

A J Kenny1, S L Stephenson.   

Abstract

The circulating form of atrial natriuretic factor is a 28-residue peptide containing a 17-residue disulphide-linked ring. It has important actions on the kidney, largely on its haemodynamics, and at other sites including the adrenal cortex and CNS. It has a short half-life in vivo and is rapidly inactivated when incubated with kidney microvillar membranes. Of the battery of peptidases present in that membrane, only one, endopeptidase-24.11, is responsible for initiating the attack, and this commences with hydrolysis of the Cys7-Phe8 bond within the ring. Hydrolysis at this and other points has been shown to inactivate the peptide and this information has pointed the way to the synthesis of resistant analogues.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2966745     DOI: 10.1016/0014-5793(88)80375-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  36 in total

Review 1.  Therapeutic use of atrial natriuretic factor.

Authors:  J M Connell; A G Jardine; D B Northridge
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

2.  Effect of neutral endopeptidase inhibition on the natriuresis and renal clearance of atrial natriuretic peptide in perfused rat kidney.

Authors:  M Yamaguchi; Y Hashimoto; H Itoh; K Nakao; K Inui
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

3.  Immunolocalization of hyperpolarization-activated cationic HCN1 and HCN3 channels in the rat nephron: regulation of HCN3 by potassium diets.

Authors:  Zinaeli López-González; Cosete Ayala-Aguilera; Flavio Martinez-Morales; Othir Galicia-Cruz; Carolina Salvador-Hernández; José Pedraza-Chaverri; Mara Medeiros; Ana Maria Hernández; Laura I Escobar
Journal:  Histochem Cell Biol       Date:  2015-10-29       Impact factor: 4.304

Review 4.  Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.

Authors:  H H Chen; A Cataliotti; J C Burnett
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

5.  Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity.

Authors:  Catherine Rougeot; Michaël Messaoudi; Véronique Hermitte; Anne Gaëlle Rigault; Thierry Blisnick; Christophe Dugave; Didier Desor; François Rougeon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-30       Impact factor: 11.205

6.  In vivo measurement of ANP overall turnover and identification of its main metabolic pathways under steady state conditions in humans.

Authors:  A Clerico; G Iervasi; S Berti; A Pilo; F Vitek; S Salvadori; M Marastoni; C Manfredi; M G Del Chicca; M R Iascone
Journal:  J Endocrinol Invest       Date:  1995-03       Impact factor: 4.256

7.  Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension.

Authors:  S H Fettner; S Pai; G R Zhu; T Kosoglou; C R Banfield; V Batra
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.

Authors:  M C Fournié-Zaluski; W Gonzalez; S Turcaud; I Pham; B P Roques; J B Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP.

Authors:  Ondrej Lisy; Brenda K Huntley; Daniel J McCormick; Paul A Kurlansky; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2008-07-01       Impact factor: 24.094

10.  Localization of corin and atrial natriuretic peptide expression in human renal segments.

Authors:  Liang Dong; Hao Wang; Ningzheng Dong; Ce Zhang; Boxin Xue; Qingyu Wu
Journal:  Clin Sci (Lond)       Date:  2016-06-24       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.